Copyright
©The Author(s) 2019.
World J Gastroenterol. May 14, 2019; 25(18): 2229-2239
Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2229
Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2229
Table 3 Mean short form 36 version 2 scores using the normative based scores
End of treatment | Baseline | P value | |
(n = 67) | (n = 67) | (Paired) | |
Physical functioning | 45.6 ± 11.3 | 44.4 ± 11.0 | 0.3389 |
Physical | 45.3 ± 10.8 | 42.2 ± 10.4 | 0.0152 |
Bodily pain | 46.3 ± 12.0 | 43.9 ± 11.2 | 0.1103 |
General health | 49.0 ± 10.8 | 44.6 ± 10.5 | 0.0004 |
Vitality | 50.4 ± 11.9 | 46.0 ± 10.6 | 0.0066 |
Social functioning | 45.4 ± 11.9 | 42.7 ± 12.1 | 0.0530 |
Emotional | 45.2 ± 12.1 | 41.8 ± 11.4 | 0.0272 |
Mental Health | 46.6 ± 12.6 | 44.1 ± 10.4 | 0.0287 |
Physical component summary | 46.8 ± 10.7 | 44.4 ± 9.1 | 0.0404 |
Mental component summary | 47.1 ± 13.7 | 43.6 ± 11.6 | 0.0112 |
- Citation: Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239
- URL: https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i18.2229